@inproceedings{ae64a9a482c4415bb1ea27f4336a1f4d,
title = "3p-C-NETA-TATE: a theranostic somatostatin analogue targeting neuroendocrine tumors",
abstract = "Aim: Radiolabeled somatostatin analogues such as [68Ga]Ga-DOTATATE and [177Lu]Lu-DOTATATE have become important tools for diagnosis and treatment of patients with neuroendocrine tumors. [18F]AlF-NOTA-octreotide, a promising 18F-labeled somatostatin analogue and potential alternative for 68Ga-DOTA-peptides, is currently under clinical evaluation [1]. Ideally, the same precursor (combination of chelator-linker-vector) should be used for production of both diagnostic and therapeutic radioprobes to ensure very similar (e.g. Al18F/213Bi/177Lu) or identical (e.g. complementary Tb-radionuclides) pharmacokinetic properties, allowing for accurate personalised dosimetry estimation, and radionuclide therapy of NET patients. 3p-C-NETA is a versatile chelator that can be used for both diagnostic and therapeutic applications [2, 3]. We have recently reported promising results for [18F]AlF-3p-C-NETA-TATE [2] and here we present the first results of radiosynthesis and in vitro evaluation of [213Bi]Bi-3p-C-NETA-TATE and [177Lu]Lu-3p-C-NETA-TATE.",
keywords = "Cancer therapy, Radionuclide, Hyperthermia",
author = "Stephen Ahenkorah and Erika Murce and Christopher Cawthorne and Yann Seimbille and Thomas Cardinaels and Christophe Deroose and Guy Bormans and Maarten Ooms and Frederik Cleeren",
note = "Score=3; 2022 - ESRR : 20th European Symposium on Radiopharmacy and Radiopharmaceuticals ; Conference date: 24-11-2022 Through 27-11-2022",
year = "2023",
month = jun,
day = "15",
doi = "10.1186/s41181-023-00193-4#Sec37",
language = "English",
volume = "8",
series = "EJNMMI Radiopharmacy and Chemistry ",
publisher = "Springer",
number = "Supplement 1",
pages = "6--6",
booktitle = "Abstracts from the 20th European symposium on radiopharmacy and radiopharmaceuticals",
address = "Netherlands",
edition = "1",
}